YM BIOSCIENCES REPORTS THIRD QUARTER 2009 OPERATIONAL AND FINANCI...(1777864 4832619 5478264 Exp...)

Date:5/14/2009

1,777,864 4,832,619 5,478,264 Expenses: General and adminis- trative 1,190,039 1,416,872 3,530,626 5,526,388 Licensing and product development 3,259,177 4,286,792 11,525,789 12,052,278 ------------------------------------------------------------------------- 4,449,216 5,703,664 15,056,415 17,578,666 ------------------------------------------------------------------------- Loss before the undernoted (3,471,454) (3,925,800) (10,223,796) (12,100,402) Gain on foreign exchange 51,122 15,584 143,009 29,716 Gain (loss) on short- term deposits (54,507) 91,569 (31,789) 217,985 Loss on disposal of property and equipment - - - (70,143) Other income - - 307,140 - ------------------------------------------------------------------------- Loss and comprehensive loss for the period $ (3,474,839) $ (3,818,647) $ (9,805,436) $ (11,922,844) ------------------------------------------------------------------------- ------------------------------------------------------------------------- Basic and diluted loss per common share $ (0.06) $ (0.07) $ (0.18) $ (0.21) ------------------------------------------------------------------------- ------------------------------------------------------------------------- Weighted average number of common shares outstanding 55,835,356 55,835,356 55,835,356 55,835,356 ------------------------------------------------------------------------- -----------------------------------------------------
'/>"/>

SOURCE YM BioSciences Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11
Related biology technology :

1. Frost & Sullivan Awards Precision Biosciences for Technology Innovation and Molecular Design Process in the Genomics Market
2. Neurocrine Biosciences to Present at the Deutsche Bank 34th Annual Health Care Conference
3. MichBio Leader Cites New Senate Biosciences Task Force and House Subcommittee as Evidence of States Growing Awareness of Industrys Economic Importance
4. Neurocrine Biosciences Reports First Quarter 2009 Results
5. Sangamo BioSciences Receives $100,000 Grand Challenges Explorations Grant for Innovative Global Health Research
6. Sangamo BioSciences Announces Publication in Nature of the Use of Zinc Finger Nucleases to Accelerate Precision Trait Stacking in Commercial Crop Species
7. ImQuest BioSciences and Arisyn Therapeutics Announce Strategic Partnership to Develop Infectious Disease and Cancer Drugs
8. LaVoie Group Selected by Vaccine Developer, Profectus BioSciences, as Agency of Record
9. Former GE Healthcare Director, Per Foss Appointed CEO for HUNT Biosciences
10. Sangamo BioSciences Announces First Quarter 2009 Conference Call and Webcast
11. Cell Biosciences Launches Next-Generation Protein Characterization System